US Unemployment Looms As A Threat To Pharma, But More Impact In 2021
Executive Summary
Sweeping job losses in the US have left people uninsured or transitioning from private insurance to Medicaid, which will impact how drugs are reimbursed. Changing payer mix will have an effect on company revenues.
You may also be interested in...
Price Inflation Rebates And The Spectre Of 100% Discounts In Medicare Part D
Medicaid programs are essentially getting Humira for free, in large part because of price inflation rebates, according to estimates by Bernstein analysts. Legislation pending in the US Senate wants to bring that dynamic to Medicare.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.